Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 7951 AL 7965

Effects of the SGLT2 inhibitor dapagliflozin in early Alzheimer's disease: A randomized controlled trial

Burns JM, Morris JK, Vidoni ED, Wilkins HM, Choi IY, Lee P, Hunt SL, Mahnken JD, Brooks WM, Lepping RJ, Gupta A, Esterline R, Oscarsson J, Swerdlow RH.

Alzheimers Dement. 2025 Jun;21(6):e70416. doi: 10.1002/alz.70416.

Comparisons of efficacy and safety of immunotherapies for Alzheimer's disease treatment: A network meta-analysis of randomised controlled trials

Su CH, Chang YT, Tseng HS, Kuo CY, Chen JH, Chien PY, Chang YJ, Hung CC.

Clin Med (Lond). 2025 Jul;25(4):100336. doi: 10.1016/j.clinme.2025.100336. Epub 2025 Jun 3.

Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial

Edison P, Femminella GD, Ritchie C, Nowell J, Holmes C, Walker Z, Ridha B, Raza S, Livingston NR, Frangou E, Love S, Williams G, Lawrence R, Mcfarlane B, Archer H, Coulthard E, Underwood BR, Koranteng P, Karim S, Bannister C, Perneczky R, Prasanna A, Junaid K, McGuinness B, Nilforooshan R, Macharouthu A, Donaldson A, Thacker S, Russell G, Malik N, Mate V, Knight L, Kshemendran S, Holscher C, Mansouri A, Chester-Jones M, Holmes J, Tan T, Williams S, Ashraf A, Brooks DJ, Harrison J, Hinz R, Tadros G, Passmore AP, Ballard C.

Nat Med. 2026 Jan;32(1):353-361. doi: 10.1038/s41591-025-04106-7. Epub 2025 Dec 1.

Efficacy and safety of passive immunotherapies targeting amyloid beta in Alzheimer's disease: A systematic review and meta-analysis

Tonegawa-Kuji R, Hou Y, Hu B, Lorincz-Comi N, Pieper AA, Tousi B, Leverenz JB, Cheng F.

PLoS Med. 2025 Mar 31;22(3):e1004568. doi: 10.1371/journal.pmed.1004568. eCollection 2025 Mar.

Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial

Bateman RJ, Li Y, McDade EM, Llibre-Guerra JJ, Clifford DB, Atri A, Mills SL, Santacruz AM, Wang G, Supnet C, Benzinger TLS, Gordon BA, Ibanez L, Klein G, Baudler M, Doody RS, Delmar P, Kerchner GA, Bittner T, Wojtowicz J, Bonni A, Fontoura P, Hofmann C, Kulic L, Hassenstab J, Aschenbrenner AJ, Perrin RJ, Cruchaga C, Renton AE, Xiong C, Goate AA, Morris JC, Holtzman DM, Snider BJ, Mummery C, Brooks WS, Wallon D, Berman SB, Roberson E, Masters CL, Galasko DR, Jayadev S, Sanchez-Valle R, Pariente J, Kinsella J, van Dyck CH, Gauthier S, Hsiung GR, Masellis M, Dubois B, Honig LS, Jack CR, Daniels A, Aguillón D, Allegri R, Chhatwal J, Day G, Fox NC, Huey E, Ikeuchi T, Jucker M, Lee JH, Levey AI, Levin J, Lopera F, Roh J, Rosa-Neto P, Schofield PR; Dominantly Inherited Alzheimer's Disease–Trials Unit.

Lancet Neurol. 2025 Apr;24(4):316-330. doi: 10.1016/S1474-4422(25)00024-9.

The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6

Wang H, Nery ESM, Ardayfio P, Khanna R, Svaldi DO, Shcherbinin S, Xu W, Andersen SW, Hauck PM, Brooks DA, Collins EC, Salloway S, Mintun MA, Sims JR.

J Prev Alzheimers Dis. 2025 Sep;12(8):100266. doi: 10.1016/j.tjpad.2025.100266. Epub 2025 Jul 5.

The Role of Magnesium in Depression, Migraine, Alzheimer's Disease, and Cognitive Health: A Comprehensive Review

Varga P, Lehoczki A, Fekete M, Jarecsny T, Kryczyk-Poprawa A, Zábó V, Major D, Fazekas-Pongor V, Csípő T, Varga JT.

Nutrients. 2025 Jul 4;17(13):2216. doi: 10.3390/nu17132216.

A randomized clinical trial of low-dose cannabis extract in Alzheimer's disease

Cury RM, da Silva T, Cezar-Dos-Santos F, Fakih YRC, Narvaez KAR, Gouvea MC, Espínola C, Ferreira CF, de Castro WAC, Pamplona FA, Silva EGD, Bicca MA, Nascimento FP.

J Alzheimers Dis. 2025 Dec;108(4):1602-1613. doi: 10.1177/13872877251389608. Epub 2025 Oct 29.

Donanemab exposure-response in early symptomatic Alzheimer's disease

Gueorguieva I, Chow K, Chua L, Shcherbinin S, Zimmer JA, Evans CD, Wang H, Nery ESM, Brooks DA, Sims JR.

Alzheimers Dement. 2025 Jul;21(7):e70491. doi: 10.1002/alz.70491.

Effects of 52 weeks of precuneus rTMS in Alzheimer's disease patients: a randomized trial

Koch G, Casula EP, Bonnì S, Borghi I, Assogna M, Di Lorenzo F, Esposito R, Maiella M, D'Acunto A, Ferraresi M, Mencarelli L, Pezzopane V, Motta C, Santarnecchi E, Bozzali M, Martorana A.

Alzheimers Res Ther. 2025 Apr 2;17(1):69. doi: 10.1186/s13195-025-01709-7.

TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease

Salloway S, Pain A, Lee E, Papka M, Ferguson MB, Wang H, Hu H, Lu M, Oru E, Ardayfio PA, Hoban DB, Collins EC, Brooks DA, Sims JR.

Alzheimers Dement. 2025 May;21(5):e70293. doi: 10.1002/alz.70293.

Systematic review and meta-analysis of bulk RNAseq studies in human Alzheimer's disease brain tissue

Aguzzoli Heberle B, Fox KL, Lobraico Libermann L, Ronchetti Martins Xavier S, Tarnowski Dallarosa G, Carolina Santos R, Fardo DW, Wendt Viola T, Ebbert MTW.

Alzheimers Dement. 2025 Mar;21(3):e70025. doi: 10.1002/alz.70025.

Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease

Chen C, Katayama S, Lee JH, Lee JY, Nakagawa M, Torii K, Ogawa T, Dash A, Irizarry M, Dhadda S, Kanekiyo M, Hersch S, Iwatsubo T.

J Prev Alzheimers Dis. 2025 May;12(5):100160. doi: 10.1016/j.tjpad.2025.100160. Epub 2025 Apr 5.

Clinical Benefits and Risks of Antiamyloid Antibodies in Sporadic Alzheimer Disease: Systematic Review and Network Meta-Analysis With a Web Application

Jeremic D, Navarro-Lopez JD, Jimenez-Diaz L.

J Med Internet Res. 2025 Apr 7;27:e68454. doi: 10.2196/68454.

Donanemab in preclinical Alzheimer's disease: Screening and baseline data from TRAILBLAZER-ALZ 3

Yaari R, Holdridge KC, Williamson M, Wessels AM, Shcherbinin S, Kotari V, Reiman EM, Tariot PN, Alexander R, Langbaum JB, Sims JR.

Alzheimers Dement. 2025 Sep;21(9):e70662. doi: 10.1002/alz.70662.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias